Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mary Dillhoff is active.

Publication


Featured researches published by Mary Dillhoff.


Journal of The National Comprehensive Cancer Network | 2017

Pancreatic adenocarcinoma, version 2.2017: Clinical practice guidelines in Oncology

Margaret A. Tempero; Mokenge P. Malafa; Mahmoud M. Al-Hawary; Horacio J. Asbun; Andrew Bain; Stephen W. Behrman; Al B. Benson; Ellen F. Binder; Dana Backlund Cardin; Charles Cha; E. Gabriela Chiorean; Vincent Chung; Brian G. Czito; Mary Dillhoff; Efrat Dotan; Cristina R. Ferrone; Jeffrey M. Hardacre; William G. Hawkins; Joseph M. Herman; Andrew H. Ko; Srinadh Komanduri; Albert C. Koong; Noelle K. LoConte; Andrew M. Lowy; Cassadie Moravek; Eric K. Nakakura; Eileen Mary O'Reilly; Jorge Obando; Sushanth Reddy; Courtney L. Scaife

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.


The Japanese Journal of Thoracic and Cardiovascular Surgery | 2011

Atrial fibrillation after esophagectomy: an indicator of postoperative morbidity.

Stanislaw P. Stawicki; Mark P. Prosciak; Anthony T. Gerlach; Mark Bloomston; H. Tracy Davido; David E. Lindsey; Mary Dillhoff; David C. Evans; Steven M. Steinberg; Charles H. Cook

PurposeThe relevance of new-onset atrial fibrillation (AF) after esophagectomy remains poorly defined. This study’s primary goal is to better define the incidence, clinical patterns, and outcomes associated with the development of AF after esophagectomy.MethodsThe study is a retrospective review of patients undergoing esophagectomy at a single academic center between May 1996 and December 2007. Patients with new-onset AF were evaluated by univariate and multivariate analyses for risk factors associated with AF onset and outcomes.ResultsNew-onset AF was noted in 32 of 156 (20.5%) patients after esophagectomy. Most (16/32, 50%) developed AF within 48 h, and 28 of 32 (87.5%) developed new AF within 72 h of surgery. Pulmonary complications were more frequent in patients with AF than those without AF (59.4% vs. 15.3%, P < 0.01) and usually immediately preceded or occurred concurrently with AF. Anastomotic leaks were significantly more common in patients with AF than those without (28.1% vs. 6.45%, P < 0.01) and were identified, on average, 4.2 days after the onset of AF. In the multivariate analysis, anastomotic leaks, pulmonary complications, and number of complications were significantly associated with AF. Although 60-day survival was worse for patients developing AF (P < 0.01), multivariate analysis suggests that non-AF complications were the independent predictor of mortality.ConclusionNew-onset AF after esophagectomy is associated with anastomotic leaks, pulmonary complications, and decreased 60-day survival. Although pulmonary complications typically occurred coincident with the onset of AF, anastomotic leaks were usually diagnosed 4 days after AF onset. New postesophagectomy AF should prompt vigilance for the presence of other concurrent complications.


Annals of Surgical Oncology | 2009

Coordinate loss of fragile gene expression in pancreatobiliary cancers: Correlations among markers and clinical features

Mark Bloomston; Jeffrey Kneile; Matthew Butterfield; Mary Dillhoff; Peter Muscarella; E. Christopher Ellison; W. Scott Melvin; Carlo M. Croce; Flavia Pichiorri; Kay Huebner; Wendy L. Frankel

BackgroundLoss of expression of fragile gene products, Fhit and Wwox, occurs in many cancer types, with loss exhibited early in the neoplastic process in some. Wwox has been understudied in pancreatobiliary cancers, especially in relation to other involved tumor suppressors. We have assessed the status of the Fhit and Wwox proteins encoded by DNA damage susceptible chromosome fragile sites encompassed by FHIT and WWOX tumor suppressor genes.MethodsPancreatic, gallbladder and ampullary cancers, normal pancreas, chronic pancreatitis, and benign gallbladder specimens were stained for expression of Fhit, Fhit effector protein Fdxr, Wwox, and other tumor suppressors by immunohistochemistry, and comparisons were made between benign and malignant tissue. Correlations of expression among proteins and clinicopathologic features were sought using Spearman’s rank order. Survival curves were created using the Kaplan-Meier method and compared by log-rank analysis. Predictors of survival were determined using multivariate Cox proportional hazards analysis.ResultsFhit and Wwox were ubiquitously expressed in benign samples and significantly and coordinately reduced in pancreatic, gallbladder, and ampullary cancers. In pancreatic cancers, Fdxr expression was positively correlated with Fhit and Wwox expression. Neither Fhit nor Wwox expression correlated with expression of other tumor suppressors or with clinicopathologic characteristics measured.ConclusionLoss of Fhit and Wwox expression does not predict tumor progression or patient survival, suggesting that loss of expression of genes at the exquisitely replication stress sensitive chromosome fragile regions is an early event in the pathogenesis of cancers of the gallbladder, pancreas, and ampulla.


Case Reports in Medicine | 2010

Two cases of small cell carcinoma of the gallbladder.

Peter Nau; James Liu; Mary Dillhoff; Meghan Forster; Jeffrey W. Hazey; Scott Melvin

Small cell carcinoma of the gallbladder is a rare disease process with approximately 40 cases reported in the literature. It is most often found in elderly female population and is associated with cholelithiasis and cigarette smoking. A multidisciplinary approach to treatment with wide surgical resection and adjuvant chemotherapy is the current standard of care. Notwithstanding prompt medical intervention, it is a disease with a poor prognosis. The pathology is characterized by early metastases and extensive local invasion. Herein, we report two cases of small cell carcinoma addressed at our institution. In both cases, a radical resection was performed with subsequent referral to oncology for additional therapy.


Annals of Surgery | 2017

A Prospective Randomized Multicenter Trial of Distal Pancreatectomy with and Without Routine Intraperitoneal Drainage

George Van Buren; Mark Bloomston; Carl Schmidt; Stephen W. Behrman; Nicholas J. Zyromski; Chad G. Ball; Katherine A. Morgan; Steven J. Hughes; Paul J. Karanicolas; John Allendorf; Charles M. Vollmer; Quan Ly; Kimberly M. Brown; Vic Velanovich; Jordan M. Winter; Amy McElhany; Peter Muscarella; C.M. Schmidt; Michael G. House; Elijah Dixon; Mary Dillhoff; Jose G. Trevino; Julie Hallet; Natalie G. Coburn; Attila Nakeeb; Kevin E. Behrns; Aaron R. Sasson; Eugene P. Ceppa; Sherif Abdel-Misih; Taylor S. Riall

Objective: The objective of this study was to test the hypothesis that distal pancreatectomy (DP) without intraperitoneal drainage does not affect the frequency of grade 2 or higher grade complications. Background: The use of routine intraperitoneal drains during DP is controversial. Prior to this study, no prospective trial focusing on DP without intraperitoneal drainage has been reported. Methods: Patients undergoing DP for all causes at 14 high-volume pancreas centers were preoperatively randomized to placement of a drain or no drain. Complications and their severity were tracked for 60 days and mortality for 90 days. The study was powered to detect a 15% positive or negative difference in the rate of grade 2 or higher grade complications. All data were collected prospectively and source documents were reviewed at the coordinating center to confirm completeness and accuracy. Results: A total of 344 patients underwent DP with (N = 174) and without (N = 170) the use of intraperitoneal drainage. There were no differences between cohorts in demographics, comorbidities, pathology, pancreatic duct size, pancreas texture, or operative technique. There was no difference in the rate of grade 2 or higher grade complications (44% vs. 42%, P = 0.80). There was no difference in clinically relevant postoperative pancreatic fistula (18% vs 12%, P = 0.11) or mortality (0% vs 1%, P = 0.24). DP without routine intraperitoneal drainage was associated with a higher incidence of intra-abdominal fluid collection (9% vs 22%, P = 0.0004). There was no difference in the frequency of postoperative imaging, percutaneous drain placement, reoperation, readmission, or quality of life scores. Conclusions: This prospective randomized multicenter trial provides evidence that clinical outcomes are comparable in DP with or without intraperitoneal drainage.


Hpb | 2016

Elevated NLR in gallbladder cancer and cholangiocarcinoma – making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium

Eliza W. Beal; Lai Wei; Cecilia G. Ethun; Sylvester M. Black; Mary Dillhoff; Ahmed Salem; Sharon M. Weber; Thuy B. Tran; George A. Poultsides; Andre Y. Son; Ioannis Hatzaras; Linda X. Jin; Ryan C. Fields; Stefan Buettner; Timothy M. Pawlik; Charles R. Scoggins; Robert C.G. Martin; Chelsea A. Isom; K. Idrees; Harveshp Mogal; Perry Shen; Shishir K. Maithel; Carl Schmidt

BACKGROUND Gallbladder and extrahepatic biliary malignancies are aggressive tumors with high risk of recurrence and death. We hypothesize that elevated preoperative Neutrophil-Lymphocyte Ratios (NLR) are associated with poor prognosis among patients undergoing resection of gallbladder or extrahepatic biliary cancers. METHODS Patients who underwent complete surgical resection between 2000-2014 were identified from 10 academic centers (n=525). Overall (OS) and recurrence-free survival (RFS) were analyzed by stratifying patients with normal (<5) versus elevated (>5) NLR. RESULTS Overall, 375 patients had NLR <5 while 150 patients had NLR >5. Median OS was 24.5 months among patients with NLR<5 versus 17.0 months among patients with NLR>5 (p<0.001). NLR was also associated with OS in subgroup analysis of patients with gallbladder cancer. In fact, on multivariable analysis, NLR>5, dyspnea and preoperative peak bilirubin were independently associated with OS in patients with gallbladder cancer. Median RFS was 26.8 months in patients with NLR<5 versus 22.7 months among patients with NLR>5 (p=0.030). NLR>5 was independently associated with worse RFS for patients with gallbladder cancer. CONCLUSIONS Elevated NLR was associated with worse outcomes in patients with gallbladder and extrahepatic biliary cancers after curative-intent resection. NLR is easily measured and may provide important prognostic information.


Surgical Oncology-oxford | 2017

Role of exosomes in treatment of hepatocellular carcinoma

Demetrios Moris; Eliza W. Beal; Jeffery Chakedis; Richard A. Burkhart; Carl Schmidt; Mary Dillhoff; Xu-Feng Zhang; Stamatios Theocharis; Timothy M. Pawlik

Exosomes are nanovesicles that may play a role in intercellular communication by acting as carriers of functional contents such as proteins, lipids, RNA molecules and circulating DNA from donor to recipient cells. In addition, exosomes may play a potential role in immunosurveillance and tumor pathogenesis and progression. Recently, research has increasingly focused on the role of exosomes in hepatocellular carcinoma (HCC), the most common primary liver malignancy. We herein review data on emerging experimental and clinical studies focused on the role of exosomes in the pathogenesis, diagnosis, progression and chemotherapy response of patients with HCC. Beyond their diagnostic value in HCC, exosomes are involved in different mechanisms of HCC tumor pathogenesis and progression including angiogenesis and immune escape. Moreover, exosomes have been demonstrated to change the tumor microenvironment to a less tolerogenic state, favoring immune response and tumor suppression. These results underline a practical and potentially feasible role of exosomes in the treatment of patients with HCC, both as a target and a vehicle for drug design. Future studies will need to further elucidate the exact role and reliability of exosomes as screening, diagnostic and treatment targets in patients with HCC.


Pancreas | 2017

Predictors of Pancreatic Cancer–Associated Weight Loss and Nutritional Interventions

Laura Nemer; Somashekar G. Krishna; Zarine K. Shah; Darwin L. Conwell; Zobeida Cruz-Monserrate; Mary Dillhoff; Denis C. Guttridge; Alice Hinton; Andrei Manilchuk; Timothy M. Pawlik; Carl Schmidt; Erin E. Talbert; Tanios Bekaii-Saab; Phil A. Hart

Objectives Pancreatic ductal adenocarcinoma (PDAC) is often accompanied by weight loss. We sought to characterize factors associated with weight loss and observed nutritional interventions, as well as define the effect of weight loss on survival. Methods Consecutive subjects diagnosed with PDAC (N = 123) were retrospectively evaluated. Univariate analysis was used to compare subjects with and without substantial (>5%) weight loss. Multivariate logistic regression was performed to identify factors associated with weight loss, and survival analyses were performed using Kaplan-Meier curves and Cox survival models. Results Substantial weight loss at diagnosis was present in 71.5% of subjects and was independently associated with higher baseline body mass index, longer symptom duration, and increased tumor size. Recommendations for nutrition consultation and pancreatic enzyme replacement therapy occurred in 27.6% and 36.9% of subjects, respectively. Weight loss (>5%) was not associated with worse survival on multivariate analysis (hazard ratio, 1.32; 95% confidence interval, 0.76–2.30), unless a higher threshold (>10%) was used (hazard ratio, 1.77; 95% confidence interval, 1.09–2.87). Conclusions Despite the high prevalence of weight loss at PDAC diagnosis, there are low observed rates of nutritional interventions. Weight loss based on current criteria for cancer cachexia is not associated with poor survival in PDAC.


Journal of Clinical Investigation | 2017

NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development

Nivedita M. Ratnam; Jennifer M. Peterson; Erin E. Talbert; Katherine J. Ladner; Priyani Rajasekera; Carl Schmidt; Mary Dillhoff; Benjamin Swanson; Ericka Haverick; Raleigh D. Kladney; Terence M. Williams; Gustavo Leone; David J. Wang; Denis C. Guttridge

Macrophages are attracted to developing tumors and can participate in immune surveillance to eliminate neoplastic cells. In response, neoplastic cells utilize NF-κB to suppress this killing activity, but the mechanisms underlying their self-protection remain unclear. Here, we report that this dynamic interaction between tumor cells and macrophages is integrally linked by a soluble factor identified as growth and differentiation factor 15 (GDF-15). In vitro, tumor-derived GDF-15 signals in macrophages to suppress their proapoptotic activity by inhibiting TNF and nitric oxide (NO) production. In vivo, depletion of GDF-15 in Ras-driven tumor xenografts and in an orthotopic model of pancreatic cancer delayed tumor development. This delay correlated with increased infiltrating antitumor macrophages. Further, production of GDF-15 is directly regulated by NF-κB, and the colocalization of activated NF-κB and GDF-15 in epithelial ducts of human pancreatic adenocarcinoma supports the importance of this observation. Mechanistically, we found that GDF-15 suppresses macrophage activity by inhibiting TGF-β-activated kinase (TAK1) signaling to NF-κB, thereby blocking synthesis of TNF and NO. Based on these results, we propose that the NF-κB/GDF-15 regulatory axis is important for tumor cells in evading macrophage immune surveillance during the early stages of tumorigenesis.


Frontiers in Oncology | 2016

Appendiceal Mixed Adeno-Neuroendocrine Carcinoma: A Population-Based Study of the Surveillance, Epidemiology, and End Results Registry.

Shayna Brathwaite; Martha Yearsley; Tanios Bekaii-Saab; Lai Wei; Carl Schmidt; Mary Dillhoff; Wendy L. Frankel; John L. Hays; Christina Wu; Sherif Abdel-Misih

Introduction Mixed adeno-neuroendocrine carcinoma (MANEC) is a rare pathological diagnosis recently defined by the World Health Organization (WHO) in 2010. Prior to the definition by the WHO, tumors with both adenocarcinoma and neuroendocrine components were given multiple pathological designations making it difficult to characterize the disease. The aim of our study is to better characterize MANEC to better understand its natural history to influence patient care and positively impact outcomes. Materials and methods The surveillance, epidemiology, and end results program database was queried for all patients aged 18 years or older between 1973 and 2012 who had the diagnosis composite carcinoid (n = 249) of the appendix. Composite carcinoid tumors refer to tumors that have both adenocarcinoma and carcinoid tumor components present, consistent with that pathological diagnosis MANEC. For comparison, the database was also queried for carcinoid tumor of the appendix (n = 950), signet ring cell carcinoma of the appendix (n = 579), and goblet cell carcinoid (GCC) tumors of the appendix (n = 944). The data were retrospectively reviewed, and clinicopathological characteristics, treatment regimens, and survival data were obtained. Results The median age of diagnosis of MANEC tumors was 58 years of age. Eighty percent of patients were White, and 49% were female. Fifty-four percent of patients underwent hemicolectomy and 31% had partial/subtotal colectomy as their surgical management. Median overall survival for MANEC was 6.5 years (95% CI 4.5–9.7), which was statistically significantly shorter (p < 0.0001) in comparison to 13.8 years (95% CI 12.1–16.5) for GCC, 2.1 years (95% CI 1.8–2.3) for signet ring cell carcinoma, and 39.4 years (95% CI 37.1–NA) for carcinoid tumors. Discussion MANEC is a more aggressive clinical entity than both GCC of the appendix and carcinoid tumors of the appendix. Based on these findings, patients with MANEC tumors should undergo aggressive multidisciplinary cancer management.

Collaboration


Dive into the Mary Dillhoff's collaboration.

Top Co-Authors

Avatar

Carl Schmidt

The Ohio State University Wexner Medical Center

View shared research outputs
Top Co-Authors

Avatar

Timothy M. Pawlik

The Ohio State University Wexner Medical Center

View shared research outputs
Top Co-Authors

Avatar

Eliza W. Beal

The Ohio State University Wexner Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jordan M. Cloyd

The Ohio State University Wexner Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ryan C. Fields

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fabio Bagante

The Ohio State University Wexner Medical Center

View shared research outputs
Top Co-Authors

Avatar

Katiuscha Merath

The Ohio State University Wexner Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge